Advertisement

Obstructive Uropathy and Benign Prostatic Hyperplasia

  • Gerasimos Alivizatos
  • Andreas Skolarikos

Keywords

Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Detrusor Overactivity International Prostate Symptom Score Bladder Outlet Obstruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gades, N.M., Jacobson, D.J., Girman, C.J., et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int. 2005; 95(4):549–553.PubMedCrossRefGoogle Scholar
  2. Skolarikos, A., Thorpe, A.C., Neal, D.E. Lower urinary tract and benign prostatic hyperplasia. Minerva Urol. Nefrol. 2004; 56:109–122.PubMedGoogle Scholar
  3. Thorpe, A.C., Cleary, R., Coles, J., et al. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Br. J. Urol. 1994; 74:559–765.PubMedGoogle Scholar
  4. Matthiesen, T., Ritting, S., Norgaard, J.P., et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J. Urol. 1996; 156:1292–1299.PubMedCrossRefGoogle Scholar
  5. Byrne, R.L., Leung, H., Neal, D.E. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br. J. Urol. 1996; 77:627–633.PubMedGoogle Scholar
  6. Logie, J., Clifford, G.M., Farmer, R.D. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int. 2005; 95(4):557–562.PubMedCrossRefGoogle Scholar
  7. De la Rosette, J.J. What we do and don’t know about benign prostatic hyperplasia. Curr. Opin. Urol. 2000; 10:1–2.CrossRefGoogle Scholar
  8. Barry, M.J. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North Am. 1990; 17:495–507.PubMedGoogle Scholar
  9. Roberts, R.O., Jacobsen, S.J., Rhodes, T., et al. Natural history of prostatism: Impaired health states in men with lower urinary tract symptoms. J. Urol. 1997; 157:1711–1717.PubMedCrossRefGoogle Scholar
  10. Boyle, P., Robertson, C., Mazzetta, C., et al. The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU Int. 2003; 92:575–580.PubMedCrossRefGoogle Scholar
  11. Garraway, W.M., Collins, G.N., Lee, R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338:469–471.PubMedCrossRefGoogle Scholar
  12. Sarma, A.V., Wei, J.T., Jacobson, D.J., et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: The Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men’s Health study. Urology 2003; 6l:108–191.Google Scholar
  13. Steyn, M. Just old age? A study of prostatism in general practice. Fam. Pract. 1988; 5:193–195.PubMedCrossRefGoogle Scholar
  14. Hoesl, C.E., Woll, E.M., Burkart, M., et al. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur. Urol. 2005; 47(4):511–517.PubMedCrossRefGoogle Scholar
  15. Nickel, J.C., Elhilali, M., Vallancien, G., ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: Prevalence of painful ejaculation in men with clinical BPH. BJU Int. 2005; 95(4):571–574.Google Scholar
  16. Roberts, R.O., Bergstralh, E.J., Cunningham, J.M., et al. Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am. J. Epidemiol. 2004 (Feb 1); 159(3):269–276.Google Scholar
  17. Li, Z., Habuchi, T., Tsuchiya, N., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 2004; 25(2):237–240.PubMedCrossRefGoogle Scholar
  18. Berger, A.P., Kofler, K., Bektic, J., et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57:57–65.PubMedCrossRefGoogle Scholar
  19. Cazares, L.H., Adam, B.L., Ward, M.D., et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Can. Res. 2002; 8:254l–2552.Google Scholar
  20. DiSanto, M.E., Stein, R., Chang, S., et al. Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am. J. Physiol. Cell Physiol. 2003; 285:C1397–1410.PubMedGoogle Scholar
  21. Fong, Y.K., Milani, S., Djavan, B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr. Opin. Urol. 2005; 15(1):35–38.PubMedCrossRefGoogle Scholar
  22. Rhodes, T., Blue Bell, P.A., Jacobson, D., et al. Longitudinal prostate volume in a community-based sample: Long-term follow-up in the Olmsted County study of urinary symptoms and health status among men. J. Urol. 2002; l67:269.Google Scholar
  23. McConnell, D. The long-term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J. Urol. 2002; l67:264.Google Scholar
  24. Speakman, M. Tamsulosin reduces the risk of acute urinary retention. J, Urol, 2002; l67:375.Google Scholar
  25. Lucas, M.G., Stephenson, T.P., Nargund, V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. 2005; 95(3):354–357.PubMedCrossRefGoogle Scholar
  26. Neal, D.E. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet 1997; 350:305–306.PubMedCrossRefGoogle Scholar
  27. Rule, A.D., Lieber, M.M., Jacobsen, S.J. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J. Urol. 2006; 173:691–696.CrossRefGoogle Scholar
  28. McConnell, J.D., Barry, M.J., Bruskewitz, R.C., Bueschen, A.J., Denton, S.E., Holtgrewe, N.L., et al. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guideline, Number 8. Agency for Health Care Policy and Research. Publication No. 04–0583, Rockville, MD: Public Health Service, U.S. Department of Health and Human Services, February 1994.Google Scholar
  29. O’Reilly, P.H., Brooman, P.J., Farah, N.B., Mason, G.C. High pressure chronic retention. Incidence, aetiology and sinister implications. Br. J. Urol. 1986; 58:644.PubMedCrossRefGoogle Scholar
  30. George, N.G., O’Reilly, P.H., Barnard, R.G., Blacklock, N.J. High pressure chronic retention. BMJ 1983; 286:1780.PubMedGoogle Scholar
  31. George, N.G., Feneley, R.C., Roberts, J.B. Identification of the poor risk patient with “prostatism” and detrusor failure. Br. J. Urol. 1986; 58:290.PubMedGoogle Scholar
  32. Comiter, C.V., Sullivan, M.P., Schacterle, R.S., Cohen, L.H., Valla, S.V. Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J. Urol. 1997; 158:181.PubMedCrossRefGoogle Scholar
  33. Styles, R.A., Neal, D.E., Griffiths, C.J., Ramsden, P.D. Long-term monitoring of bladder pressure in chronic retention of urine: The relationship between detrusor activity and upper tract dilatation. J. Urol. 1988; 140:330.PubMedGoogle Scholar
  34. Jones, D.A., Giplin, S.A., Holden, D., Dixon, J.S., O’Reilly, P.H., George, N.J. Relationship between bladder morphology and long-term outcome of treatment in patients with high pressure chronic retention of urine. Br. J. Urol. 1991; 67:280.PubMedGoogle Scholar
  35. Sutaria, P.M., Staskin, D.R. Hydronephrosis and renal deterioration in the elderly due to abnormalities of the lower urinary tract and ureterovesical junction. Int. Urol. Nephrol. 2000; 32:119.PubMedCrossRefGoogle Scholar
  36. Prakash, J., Saxena, R.K., Sharma, O.P., Usha , Spectrum of renal diseases in the elderly: Single center experience from a developing country. Int. Urol. Nephrol. 2001; 133:227.Google Scholar
  37. Olbrich, O., Woodford-Williams, E., Irvine, R.E., Webster, D. Renal function in prostatism. Lancet 1957; 1:1322.CrossRefGoogle Scholar
  38. Ogbonna, B.C., Madziga, A.G., AnteyIi, E.A. The impact of renal impairment on the management of patients with lower urinary tract obstruction. Trop. Doct. 1997; 27:75.PubMedGoogle Scholar
  39. Bhargava, S., Canda, A.E., Chapple, C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr. Opin. Urol. 2004; 14(1):1–6.PubMedCrossRefGoogle Scholar
  40. Mebust, W., Roizo, R., Schroeder, F., et al. Correlations between pathology clinical symptoms and the course of the disease. In Proceedings of the International Consultation on Benign Protastic Hyperplasia, A.T.K. Cockett, Y. Aso, C. Chatelain, L. Denis, K. Griffiths, S. Khoury, et al., eds. Geneva: WHO. 1991; pp. 51–62.Google Scholar
  41. Bosch, J.L., Hop, W.C., Kirkels, W.J., et al. The international prostate symptom score in a community sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age. Prostate volume, flow rate and residual urine volume. Br. J. Urol. 1995; 75:622–630.PubMedGoogle Scholar
  42. Djavan, B., Wammack, R., Dobrovits, M., et al. Predictors of progression in men with mild symptoms of bladder outlet obstruction. J. Urol. 2002; 167:268.CrossRefGoogle Scholar
  43. Tubaro, A., Trucchi, A., Miano, L. Investigation of benign prostatic hyperplasia. Curr. Opin. Urol. 2003; 13:17–22.PubMedCrossRefGoogle Scholar
  44. Braun, M.H., Sommer, F., Haupt, G., et al. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical “Aging Male”’ symptoms? Results of the “Cologne Male Survey.” Eur. Urol. 2003; 44:588–594.PubMedCrossRefGoogle Scholar
  45. Chatelain, C., Denis, L., Foo, K.T., Khoury, S., Connell, J.M.C. Benign Prostatic Hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), June 25–28, 2000, Paris. Plymouth, UK: Health Publication Ltd. 2001.Google Scholar
  46. Di Silverio, F., Sciarra, A., D’Eramo, G., et al. Relationship among age, prostate specific antigen and prostate volume in men with lower urinary tract symptoms and in different age groups of men with and without benign and malignant prostatic diseases. Prostate 1998; 36:l–7.CrossRefGoogle Scholar
  47. Roehrborn, C.G. The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004; 93(Suppl 1):21–26.CrossRefGoogle Scholar
  48. Laniado, M.E., Ockrim, J.L., Marronaro, A., et al. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int. 2004; 94(9):1283–1286.PubMedCrossRefGoogle Scholar
  49. Wright, E.J., Fang, J., Metter, E.J., et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J. Urol. 2002; 167:2484–2488.PubMedCrossRefGoogle Scholar
  50. Chatelain, C.H., Denis, L., Foo, K.T., et al. Evaluation and treatment of lower urinary tract symptoms in older men. Recommendations of the 5th International Consultation on Benign Prostatic Hyperplasia. June 25–28, 2000. Paris, Plymouth, UK: Health Publication Ltd. 2001; pp. 519–533.Google Scholar
  51. Flanigan, R.C., Reda, D.J., Wasson, J.H., et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. A Department of Veterans Affairs cooperative study. J. Urol. 1998; l60:12–16.Google Scholar
  52. AUA Practice Guidelines Committee. AUA guideline of management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J. Urol. 2003; 170:530–547.CrossRefGoogle Scholar
  53. Souverein, P.C., van Reimsdijk, M.M., de la Rosette, J.J., et al. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: A population-based cohort study in the Netherlands. Eur. Urol. 2005; 47(4):505–510.PubMedCrossRefGoogle Scholar
  54. de Nunzio, C., Franko, G., Rocchegiani, A., et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J. Urol. 2003; 169(2):535–539.PubMedCrossRefGoogle Scholar
  55. Borth, C.S., Beiko, D.T., Nickel, J.C. Impact of medical therapy on transurethral resection of the prostate: A decade of change. Urology 2001; 57:1082–1085.PubMedCrossRefGoogle Scholar
  56. Fong, Y.K., Milani, S., Djavan, B. Role of phytotherapy in men with lower urinary tract symptoms. Curr. Opin. Urol. 2005; 15(1):45–48.PubMedCrossRefGoogle Scholar
  57. Lowe, F.C., Fagelman, E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2002; 12:15–18.PubMedCrossRefGoogle Scholar
  58. Debruyne, F., Koch, G., Boyle, P., et al. Comparison of a phytotherapeutic agent (permixon) with an a-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur. Urol. 2002; 4l:497–506, discussion 506–507.CrossRefGoogle Scholar
  59. Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E.S., Goldberg, H., Avins, A.L. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 2006; 354(6):557–566.PubMedCrossRefGoogle Scholar
  60. Talpur, N., Echard, B., Bagchi, D., et al. Comparison of saw palmetto (extract and whole berry) and Cemitin on prostate growth in rats. Mol. Cell Biochem. 2003; 250:21–26.PubMedCrossRefGoogle Scholar
  61. Wadsworth, T.L., Carroll, J.M., Mallinson, R.A., et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004; 145(7):3205–3214.PubMedCrossRefGoogle Scholar
  62. Lepor, H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol. 1998; 81:29–33.PubMedGoogle Scholar
  63. Kyprianou, N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J. Urol. 2003; 169:1520–1525.PubMedCrossRefGoogle Scholar
  64. Forray, C., Bard, J.A., Wetzel, J.M., et al. The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned alphaC subtype. Mol. Pharmacol. 1994; 45:703–708.PubMedGoogle Scholar
  65. Chapple, C.R. α-adrenoceptor antagonists in the year 2000: Is there anything new? Curr. Opin. Urol. 2001; 11:9–16.PubMedCrossRefGoogle Scholar
  66. Narayan, P., Evans, C.P., Moon, T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J. Urol. 2003; 170(2 Pt 1):498–502.PubMedCrossRefGoogle Scholar
  67. Nordling, J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005; 95(7):1006–1012.PubMedCrossRefGoogle Scholar
  68. Bartsch, G., Rittmaster, R.S., Klocker, H. Dihydrotestosterone and the concept of 5-α reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 2000; 37:367–380.PubMedCrossRefGoogle Scholar
  69. Clark, R., Hermann, D., Gabriel, H., et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5-α reductase inhibitor. J. Urol. 1999; 161:1037.CrossRefGoogle Scholar
  70. Roehrborn, C.G., Bruskewitz, R., Nickel, G.C., et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur. Urol. 2000; 37:528–536.PubMedCrossRefGoogle Scholar
  71. Andriole, G.L., Kirby, R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 2003; 44:82–88.PubMedCrossRefGoogle Scholar
  72. Lam, J.S., Romas, N.A., Lowe, F.C. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003; 61:354–358.PubMedCrossRefGoogle Scholar
  73. Wesselis, H., Roy, J., Bannow, J., et al. PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61:579–584.CrossRefGoogle Scholar
  74. Desgrandchamps, F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: A reflection from MTOPS. Curr. Opin. Urol. 2004; 14(1):17–20.PubMedCrossRefGoogle Scholar
  75. Baldwin, K.G., Ginsberg, P.C., Roehrborn, C.G., et al. Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58:203–209.PubMedCrossRefGoogle Scholar
  76. Reynard, J.M. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr. Opin. Urol. 2004; 14(1):13–16.PubMedCrossRefGoogle Scholar
  77. Freyer, P. One thousand cases of total enucleation of the prostate for radical cure of enlargement of that organ. BMJ 1912; 2:868.Google Scholar
  78. Millin, T. Retropubic Urinary Surgery. London: Livingstone. 1947.Google Scholar
  79. Walsh, T.N., Kelly, D.G. Historical review of prostatectomy. In The Prostate, J.M. Fitzpatrick and R.J. Krane, eds. London: Churchill Livingstone. 1989; pp. l43–147.Google Scholar
  80. Blandy, J.P. Transurethral prostatectomy. In The Prostate, J.R. Blandy and B. Lytton, eds. London: Butterworth. 1986; pp. 51–61.Google Scholar
  81. Walsh, A. Indications for prostatic surgery and selection of operation. In The Prostate, J.M. Fitzpatrick and R.J. Krane, eds. London: Churchill Livingstone. 1989; pp. l37–142.Google Scholar
  82. Thomas, A.W., Cannon, A., Bartlett, E., et al. The natural history of lower urinary tract dysfunction in men: The influence of detrusor under-activity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004; 93(6):745–750.PubMedCrossRefGoogle Scholar
  83. Roos, N.P., Wennberg, J.E., Malenka, D.J., et al. Mortality and re-operation after open and transurethral resection of the prostate. N. Engl. J. Med. 1989; 320:1120–1124.PubMedCrossRefGoogle Scholar
  84. Brookes, S.T., Donovan, J.L., Peters, T.J., et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: Evidence from randomized controlled trial. BMJ 2002; 324:1059–1061.PubMedCrossRefGoogle Scholar
  85. Smith, D., Khoubehi, B., Patel, A. Bipolar electrosurgery for benign prostatic hyperplasia: Transurethral electrovaporization and resection of the prostate. Curr. Opin. Urol. 2005; 15(2):95–100.PubMedCrossRefGoogle Scholar
  86. Wilson, J.R., Urwin, G.H., Stower, M.J. The changing practice of transurethral prostatectomy: A comparison of cases performed in 1990 and 2000. Ann. Roy. Coll. Surg. Engl. 2004; 86(6):428–431.CrossRefGoogle Scholar
  87. Pickard, R., Emberton, M., Neal, D.E. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br. J. Urol. 1998; 81(5):712–720.PubMedGoogle Scholar
  88. Ghalayini, I.F., Al-Ghazo, M.A., Pickard, R.S. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention. BJU Int. 2005; 96(1):93–97.PubMedCrossRefGoogle Scholar
  89. Emberton, M., Neal, D.E., Black, N., et al. Effect of prostatectomy on symptom scoring and quality of life. Br. J. Urol. 1996; 77:233–247.PubMedGoogle Scholar
  90. Kabelin, J.R., Gillings, P.J., Praundorfer, M.R. Hoimiumyttrium-aluminium-garnet laser prostatectomy. Mayo Clinic Proc. 1998; 73:792–797.Google Scholar
  91. Tan, A.H., Gilling, P.J. Lasers in the treatment of benign prostatic hyperplasia: An update. Curr. Opin. Urol. 2005; 15(1):55–58.PubMedCrossRefGoogle Scholar
  92. Barber, N.J., Muir, G.H. High-power KTP laser prostatectomy: The new challenge to transurethral resection of the prostate. Curr. Opin. Urol. 2004; 14(1):21–25.PubMedCrossRefGoogle Scholar
  93. Hoffman, R.M., MacDonald, R., Wilt, T.J. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst. Rev. 2004; (1):CD001987.Google Scholar
  94. Seki, N., Mochida, O., Kinukawa, N., et al. Holmium laser enucleation for prostatic adenoma: Analysis of learning curve over the course of 70 consecutive cases J. Urol. 2003; 170:1847–1850.PubMedCrossRefGoogle Scholar
  95. Naspro, R., Salonia, A., Colombo, R., et al. Update of the minimally invasive therapies for benign prostatic hyperplasia. Curr. Opin. Urol. 2005; 15(1):49–53.PubMedCrossRefGoogle Scholar
  96. Denovec, M., Houdelette, P. Columbeau, P., et al. A multicenter study of SHAM versus thermotherapy in benign prostatic hypertrophy. J. Urol. 1994; 151:415.Google Scholar
  97. Hoffman, R.M., MacDonald, R., Monga, M., et al. Transurethral microwave thermotherapy vs. transurethral resection for treating benign prostatic hyperplasia: A systematic review. BJU Int. 2004; 94(7):1031–1036.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Gerasimos Alivizatos
  • Andreas Skolarikos

There are no affiliations available

Personalised recommendations